Vp, Global Medical Lead, Solid Tumours

**Site Name**: UK - London - Brentford, Baar Onyx, USA - Massachusetts - Waltham, USA - Pennsylvania - Upper Providence
**Posted Date**: Sep 20 2024
We’re excited to be moving to our vibrant new home on New Oxford Street in central London from the end of June 2024. At GSK HQ, we’re building an energising space where we can connect, collaborate and get ahead of disease together. Designed especially for us, it’ll be one of the healthiest workplaces in the world, with best-in-class tech and bright, light spaces to help us thrive.

**Job Purpose**

The VP, Global Medical Lead, niraparib is a key senior business leadership role, reporting to the VP, Global Medical Affairs Oncology TA Head who is a key member of GSK’s Global Medical Leadership Team.

The leader will have full responsibility for the Global Medical Strategy for niraparib. The Global Medical Strategy Lead will lead the translation of our science to shape the practice of medicine and deliver positive health impact for patients by providing healthcare decision-makers around the world with the evidence and confidence they need on GSK therapies, and influencing internal stakeholders with medical insight and expertise related to Development and Commercialization strategies. The role will be accountable for the Medical strategic direction of an Asset or Portfolio of assets and the matrix leadership of the Global Asset Medical Leadership Team, integrating innovative strategies that advance patient care and help shape the practice of medicine. The role will partner with key markets to ensure that their insights are used to inform all evidence, asset/vaccine development and strategic deliverables as well as partnering across Commercial and R&D to deliver value for patients.

In addition to leading the Global Medical Leadership team for Niraparib, the incumbent will be a member of several additional matrix teams including the Medicines Development Team and the Medicine Commercial Team where he or she will provide Medical insight and expertise to inform and influence evidence generation and scientific communication plans across the lifecycle to optimize patient impact within markets.

A key focus of the role is to develop and stretch self and team to be best in the industry at delivering impact for patients and improving patient care paradigms.

**Key Responsibilities**
- **Lead the cross-functional global medical team and influence product development at the global level**:

- ** As chair of the global medical team**
- Jointly accountable for developing the global medical brand strategy and plans for a product by convening the global medical team
- Set direction along strategic framework of the medical brand plan including setting scientific objectives, own the medical scientific narrative and the integrated communication plan
- Accountable for directing and coordinating global resources to generate data and create content to support priority markets, leveraging the expertise of the Global operations team and Global data team
- Represent medical in cross-functional strategy meetings and workshops, and proactively offer options for innovative medical strategy for the IAP at the MDT and MCT meetings
- Provide focused support at key inflection points during development (e.g., launch)
- ** As Lead and Chair of the cross-functional global medical team**
- Responsible for representing the voice of the CPO organisation for a priority product
- Accountable for all medical activities related to product development at the global level
- Lead, coach, and mentor direct reports that support the global medical in development of medical brand strategy and plans, and execute and/or support execution of global tactics
- Address broader holistic disease area considerations as they arise by convening other relevant medical leads ad-hoc
- Play an active role within TA to articulate and implement a single, unified medical strategy across portfolio

**Enterprise Leadership**:

- Maximize the positive impact for patients and GSK from early development to maturity (defined as no further significant clinical evidence generation).
- Act as a partner to the MDL and MCL, ensure integrated and thoughtful insights from across a diverse stakeholder set contribute to shaping the medicines vision, development strategy and clinical development in the early phases of development, and for refining medical strategy as clinical evidence is generated.
- Ensure that medical insights from the priority markets are incorporated into the GMT to inform all evidence, product development, and asset strategy deliverables.
- Accountable for leading the GMT in the development and delivery of the Global medical product strategy and associated global deliverables enabling prioritized LOCs to execute the strategy and deliver positive patient impact locally.
- Ensure that the evidence generation plan aligns to identified unmet needs and prioritized evidence gaps and addresses key medical and market acces